Gemma Pujol-Muncunill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gemma Pujol-Muncunill has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Víctor Manuel Navas-López
Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Malaga, 29010 Málaga, Spain
7 shared publications - Ana Moreno-Álvarez
Gastroenterología y Nutrición Pediátrica Complejo Hospitalario Universitario A Coruña, Coruña, Spain
4 shared publications - Javier Martín de Carpi
Department of Pediatric Gastroenterology, Hepatology and Nutrition Hospital Sant Joan de Deu Barcelona Spain
4 shared publications - Alejandro Rodríguez-Martínez
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain
3 shared publications - Alfonso Solar-Boga
Pediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Pediatrics, A Coruña University Hospital, Area Sanitaria A Coruña-Cee, 15006 A Coruña, Spain
3 shared publications - Marta Velasco Rodríguez-Belvís
Department of Pediatric Gastroenterology and Nutrition Hospital Infantil Universitario Niño Jesús Madrid Spain
3 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.
- 5 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessEfficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.
- 3 June 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (2) , 425-431
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience
Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of tofacitinib in pediatric UC. Methods: This is a retrospective review of children diagnosed with UC treated with tofacitinib from 16 pediatric centers internationally. The primary outcome was week 8 corticosteroid-free clinical remission (Pediatric Ulcerative Colitis Activity Index <10). Secondary outcomes were clinical response (≥20-point decrease in Pediatric Ulcerative Colitis Activity Index) at week 8, corticosteroid-free clinical remission at week 24, and colectomy rate and adverse safety events through to last follow-up. The primary outcome was calculated by the intention-to-treat principle. Results: We included 101 children with a mean age at diagnosis of 12.8 ± 2.8 years and a median disease duration of 20 months (interquartile range [IQR], 10-39 months). All had treatment failure with at least 1 biologic agent, and 36 (36%) had treatment failure with 3 agents. Median follow-up was 24 weeks (IQR, 16-54 weeks). Sixteen (16%) children achieved corticosteroid-free clinical remission at week 8, and an additional 30 (30%) demonstrated clinical response. Twenty (23%) of 88 children achieved corticosteroid-free clinical remission at week 24. A total of 25 (25%) children underwent colectomy by median 86 days (IQR, 36-130 days). No serious drug-related adverse events were reported; there was 1 case of herpes zoster and 2 cases of minor blood test perturbations. Conclusions: In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data.
- 3 June 2024
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 31 (2) , 425-431
Tofacitinib in Pediatric Ulcerative Colitis: A Retrospective Multicenter Experience
Background: Tofacitinib has recently been approved for treatment of moderate-to-severe ulcerative colitis (UC) in adults, yet pediatric data are limited. This international multicenter study describes the effectiveness and safety of tofacitinib in pediatric UC. Methods: This is a retrospective review of children diagnosed with UC treated with tofacitinib from 16 pediatric centers internationally. The primary outcome was week 8 corticosteroid-free clinical remission (Pediatric Ulcerative Colitis Activity Index <10). Secondary outcomes were clinical response (≥20-point decrease in Pediatric Ulcerative Colitis Activity Index) at week 8, corticosteroid-free clinical remission at week 24, and colectomy rate and adverse safety events through to last follow-up. The primary outcome was calculated by the intention-to-treat principle. Results: We included 101 children with a mean age at diagnosis of 12.8 ± 2.8 years and a median disease duration of 20 months (interquartile range [IQR], 10-39 months). All had treatment failure with at least 1 biologic agent, and 36 (36%) had treatment failure with 3 agents. Median follow-up was 24 weeks (IQR, 16-54 weeks). Sixteen (16%) children achieved corticosteroid-free clinical remission at week 8, and an additional 30 (30%) demonstrated clinical response. Twenty (23%) of 88 children achieved corticosteroid-free clinical remission at week 24. A total of 25 (25%) children underwent colectomy by median 86 days (IQR, 36-130 days). No serious drug-related adverse events were reported; there was 1 case of herpes zoster and 2 cases of minor blood test perturbations. Conclusions: In this largest real-life pediatric cohort to date, tofacitinib was effective in at least 16% of patients with highly refractory UC by week 8. Adverse events were minor and largely consistent with adult data.
- 21 May 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (8) , 3417-3430
Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP
IMPACT-III and IMPACT-III-P are health-related quality of life (HRQoL) questionnaires for patients with pediatric inflammatory bowel disease (p-IBD) and their parents/caregivers. We aimed to perform a transcultural adaptation and validation for the Spanish context. Translation, back-translation, and evaluation of the questionnaires were performed by an expert committee and 12 p-IBD families. We recruited p-IBD patients aged 10–17 and their parents/caregivers. Utility, content, and face validity were considered. Validation was performed with Cronbach’s alpha coefficient and varimax rotation. We confirmed the adequacy of the factor analysis using Kaiser–Meyer–Olkin (KMO) and Bartlett’s sphericity tests. A confirmatory factor analysis was performed using the following goodness indexes: chi-square, Normed Fit Index (NFI), Root Mean Square Error of Approximation index (RMSEA), Standardized Root Mean Square Residual (SRMR), and Comparative Fit Index (CFI). The correlation coefficient between IMPACT-III and IMPACT-III-P was analyzed. We included 370 patients and 356 parents/caregivers (37 hospitals). Both questionnaires had good content and face validity and were considered user-friendly. The KMO measure (0.8998 and 0.9228, respectively) and Bartlett’s sphericity test (p-value < 0.001 for both) confirmed the adequacy of the factor analysis. The 4-factor model, complying with Kaiser’s criterion, explained 89.19% and 88.87% of the variance. Cronbach’s alpha (0.9123 and 0.9383) indicated excellent internal consistency. The CFA showed an adequate fit (NFI 0.941 and 0.918, RMSEA 0.048 and 0.053, SRMR 0.037 and 0.044, and CFI 0.879 and 0.913). The correlation coefficient was excellent (0.92). Conclusion: The SEGHNP versions of IMPACT-III and IMPACT-III-P are valid and reliable instruments for Spanish p-IBD families. What is Known: • IMPACT-III and parent-proxy IMPACT-III (IMPACT-III-P) are useful questionnaires for assessing health-related quality of life (HRQoL) in pediatric inflammatory bowel disease (p-IBD) patients and their parents/caregivers and have been translated and validated in several countries. • To date, no transcultural adaptation and validation of these questionnaires have been published for Spanish patients with p-IBD and their families. What is New: • This is the first transcultural adaptation and validation of IMPACT-III and IMPACT-III-P for Spanish p-IBD families. • These are valid and reliable instruments for assessing HRQoL in Spanish families of patients with p-IBD.
- 21 May 2024
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 183 (8) , 3417-3430
Transcultural adaptation and validation of IMPACT-III and IMPACT-III-P in Spanish families: a multicenter study from SEGHNP
IMPACT-III and IMPACT-III-P are health-related quality of life (HRQoL) questionnaires for patients with pediatric inflammatory bowel disease (p-IBD) and their parents/caregivers. We aimed to perform a transcultural adaptation and validation for the Spanish context. Translation, back-translation, and evaluation of the questionnaires were performed by an expert committee and 12 p-IBD families. We recruited p-IBD patients aged 10–17 and their parents/caregivers. Utility, content, and face validity were considered. Validation was performed with Cronbach’s alpha coefficient and varimax rotation. We confirmed the adequacy of the factor analysis using Kaiser–Meyer–Olkin (KMO) and Bartlett’s sphericity tests. A confirmatory factor analysis was performed using the following goodness indexes: chi-square, Normed Fit Index (NFI), Root Mean Square Error of Approximation index (RMSEA), Standardized Root Mean Square Residual (SRMR), and Comparative Fit Index (CFI). The correlation coefficient between IMPACT-III and IMPACT-III-P was analyzed. We included 370 patients and 356 parents/caregivers (37 hospitals). Both questionnaires had good content and face validity and were considered user-friendly. The KMO measure (0.8998 and 0.9228, respectively) and Bartlett’s sphericity test (p-value < 0.001 for both) confirmed the adequacy of the factor analysis. The 4-factor model, complying with Kaiser’s criterion, explained 89.19% and 88.87% of the variance. Cronbach’s alpha (0.9123 and 0.9383) indicated excellent internal consistency. The CFA showed an adequate fit (NFI 0.941 and 0.918, RMSEA 0.048 and 0.053, SRMR 0.037 and 0.044, and CFI 0.879 and 0.913). The correlation coefficient was excellent (0.92). Conclusion: The SEGHNP versions of IMPACT-III and IMPACT-III-P are valid and reliable instruments for Spanish p-IBD families. What is Known: • IMPACT-III and parent-proxy IMPACT-III (IMPACT-III-P) are useful questionnaires for assessing health-related quality of life (HRQoL) in pediatric inflammatory bowel disease (p-IBD) patients and their parents/caregivers and have been translated and validated in several countries. • To date, no transcultural adaptation and validation of these questionnaires have been published for Spanish patients with p-IBD and their families. What is New: • This is the first transcultural adaptation and validation of IMPACT-III and IMPACT-III-P for Spanish p-IBD families. • These are valid and reliable instruments for assessing HRQoL in Spanish families of patients with p-IBD.
- Open Access
- 29 June 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-7
Efficacy of Crohn’s disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review
Background: Recent trials suggested that the Crohn’s disease (CD) exclusion diet (CDED) plus partial enteral nutrition (PEN) is a safe and effective strategy in remission induction of paediatric-onset CD. However, real-world evidence regarding the safety and efficacy of the CDED plus PEN approach is still lacking. The present case-series study reported our experience with the outcomes of CDED plus PEN in the paediatric-onset CD at disease onset and after the loss of response to biologics. Methods: We conducted a retrospective chart review on children who were treated with CDED plus PEN through the period from July 2019 and December 2020. Clinical and laboratory data were retrieved and compared at baseline, 6, 12, and 24 weeks of treatment. The primary endpoint of the present study was the rate of clinical remission. Results: The present study retrieved the data from 15 patients. Of them, nine patients were treatment naïve at the time of initiation of CDED plus PEN (group A) and the remaining patients relapsed on biologics before treatment. All patients in groups A and B exhibited clinical remission in week six, which was sustained until week 12. At the end of the follow-up, the clinical remission rate was 87% and 60% in groups A and B, respectively. No side effects were observed in both groups. In group A, the faecal calprotectin (FC) and albumin improved at week six, week 12, and week 24 (p < 0.05). The erythrocyte sedimentation rate (ESR) improved significantly at week 12 (p = 0.021) and week 24 (p = 0.027). At the same time, the haemoglobin and iron levels showed significant improvement only at week 24. For group B, only FC showed numerical reductions over time that did not reach the level of statistical significance. Conclusion: Treatment with CDED plus PEN was well tolerated and achieved an excellent clinical remission rate in treatment-naive patients. However, the benefit of CDED plus PEN was less in patients who initiated the strategy after losing the response to biologics.
- 29 June 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-7
Open AccessEfficacy of Crohn’s disease exclusion diet in treatment -naïve children and children progressed on biological therapy: a retrospective chart review
Background: Recent trials suggested that the Crohn’s disease (CD) exclusion diet (CDED) plus partial enteral nutrition (PEN) is a safe and effective strategy in remission induction of paediatric-onset CD. However, real-world evidence regarding the safety and efficacy of the CDED plus PEN approach is still lacking. The present case-series study reported our experience with the outcomes of CDED plus PEN in the paediatric-onset CD at disease onset and after the loss of response to biologics. Methods: We conducted a retrospective chart review on children who were treated with CDED plus PEN through the period from July 2019 and December 2020. Clinical and laboratory data were retrieved and compared at baseline, 6, 12, and 24 weeks of treatment. The primary endpoint of the present study was the rate of clinical remission. Results: The present study retrieved the data from 15 patients. Of them, nine patients were treatment naïve at the time of initiation of CDED plus PEN (group A) and the remaining patients relapsed on biologics before treatment. All patients in groups A and B exhibited clinical remission in week six, which was sustained until week 12. At the end of the follow-up, the clinical remission rate was 87% and 60% in groups A and B, respectively. No side effects were observed in both groups. In group A, the faecal calprotectin (FC) and albumin improved at week six, week 12, and week 24 (p < 0.05). The erythrocyte sedimentation rate (ESR) improved significantly at week 12 (p = 0.021) and week 24 (p = 0.027). At the same time, the haemoglobin and iron levels showed significant improvement only at week 24. For group B, only FC showed numerical reductions over time that did not reach the level of statistical significance. Conclusion: Treatment with CDED plus PEN was well tolerated and achieved an excellent clinical remission rate in treatment-naive patients. However, the benefit of CDED plus PEN was less in patients who initiated the strategy after losing the response to biologics.
- Open Access
- 8 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 77
Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
- 8 January 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (1) , 77
Open AccessWhole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged < 18 years who started treatment with infliximab or adalimumab (29 responders and nine non-responders). Whole gene expression profiles from total RNA isolated from whole blood samples of six responders and six non-responders taken before administration of the biologic and after two weeks of therapy were analyzed using next-generation RNA sequencing. The expression of six selected genes was measured for purposes of validation in all of the 38 patients recruited using qPCR. Results: Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
- Open Access
- 9 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3364
Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
- 9 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (9) , 3364
Open AccessGene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
- Open Access
Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity.
Open AccessPredictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP
Exclusive enteral nutrition (EEN) has been shown to be more effective than corticosteroids in achieving mucosal healing in children with Crohn´s disease (CD) without the adverse effects of these drugs. The aims of this study were to determine the efficacy of EEN in terms of inducing clinical remission in children newly diagnosed with CD, to describe the predictive factors of response to EEN and the need for treatment with biological agents during the first 12 months of the disease. We conducted an observational retrospective multicentre study that included paediatric patients newly diagnosed with CD between 2014–2016 who underwent EEN. Two hundred and twenty-two patients (140 males) from 35 paediatric centres were included, with a mean age at diagnosis of 11.6 ± 2.5 years. The median EEN duration was 8 weeks (IQR 6.6–8.5), and 184 of the patients (83%) achieved clinical remission (weighted paediatric Crohn’s Disease activity index [wPCDAI] < 12.5). Faecal calprotectin (FC) levels (μg/g) decreased significantly after EEN (830 [IQR 500–1800] to 256 [IQR 120–585] p < 0.0001). Patients with wPCDAI ≤ 57.5, FC < 500 μg/g, CRP >15 mg/L and ileal involvement tended to respond better to EEN. EEN administered for 6–8 weeks is effective for inducing clinical remission. Due to the high response rate in our series, EEN should be used as the first-line therapy in luminal paediatric Crohn’s disease regardless of the location of disease and disease activity.
- Open Access
- 1 February 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 88 (2) , 89-99
Efectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
- 1 February 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 88 (2) , 89-99
Open AccessEfectividad y seguridad en nuestro entorno de adalimumab como tratamiento anti-TNF de primera linea en niños con enfermedad de Crohn
- 1 September 2017
- Published by Elsevier in Enfermedad Inflamatoria Intestinal al Día
- Vol. 16 (3) , 127-137
Metotrexato en la enfermedad inflamatoria intestinal pediátrica
- 1 September 2017
- Published by Elsevier in Enfermedad Inflamatoria Intestinal al Día
- Vol. 16 (3) , 127-137
Metotrexato en la enfermedad inflamatoria intestinal pediátrica
- 1 July 2016
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 85 (1) , 34-40
Comparison of the effectiveness and safety of polyethylene glycol with and without electrolytes in the treatment of chronic constipation
- 1 July 2016
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 85 (1) , 34-40
Comparison of the effectiveness and safety of polyethylene glycol with and without electrolytes in the treatment of chronic constipation